Private equity firms Advent International and GIC withdrew $8bn offer for Swedish Orphan Biovitrum, a firm that focuses on rare diseases, primarily in hematology and immunology. “We are as committed as ever to helping people with rare diseases. The Board and I have confidence in Sobi’s vision: To be recognised as a global leader in rare diseases. We have taken important steps towards this vision in recent years, and we are proud of the clear progress made," Håkan Björklund, Sobi Chairman.